June 22 (Reuters) – Pfizer said on Monday its drug for a type of lung cancer missed the main goal of improving survival in patients compared to a generic drug in a late-stage trial.
The drug was being tested in locally advanced, unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) who had received one or more lines of prior therapy versus docetaxel.
However, separately in patients who received only one prior line of systemic therapy, the company said the drug sigvotatug vedotin showed a stronger trend in improving survival and survival without progression of the disease versus docetaxel.
Pfizer said this reinforces its confidence in the potential of the sigvotatug vedotin program, including an ongoing late-stage trial in combination with Merck’s Keytruda.
(Reporting by Puyaan Singh in Bengaluru; Editing by Vijay Kishore)
Comments